Figure 5.

PAH restricts the host innate defense against HSV-1 infection in vivo. (A) Mice were orally administered Vehicle (0.03% CMC-Na solution) or 120 mg•kg⁻¹ PAH once per day for 14 days, then injected with HSV-1 intravenously. The time course of mice body weight. (B) Mice were orally administered Vehicle (0.03% CMC-Na solution) or 120 mg•kg⁻¹ PAH once per day for 14 days, then the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in serum were measured at the 14^th day. (C–E) Mice were treated as in (A). The concentrations of serum IFN-β of mice were measured by ELISA (C), and the levels of Ifnb, Cxcl10, Isg15, and Isg56 mRNA expression in the hearts (D) and spleens (E) of mice were measured by qPCR. (F) Schematic of drug administration and durable study after HSV-1 infection in vivo. (G) The time course of merged body weight from mice treated in (F). (H) The time course of body weight from each mouse treated in (F). Data in (A–E, G–H) are representative of two independent experiments (mean ± SD). n.s, no significance. *P < 0.05, **P < 0.01, ***P < 0.001.